WALTHAM, Mass. — CellTivity Scientific is expanding the clinical focus of its Van Gogh Microscopy System beyond lung biopsies as the company sees growing interest in the technology for cancer detection across multiple organ systems, including gynecologic and pancreatic cancer.
The Waltham-based point-of-care disease detection company said its Dynamic Cell Imaging technology is evolving from an initial pulmonary focus into a broader multi-organ, multi-specialty platform designed to support real-time decision-making during medical procedures.
“While CellTivity’s Van Gogh system is known for enhanced detection of lung cancer, we are seeing meaningful clinical interest in Dynamic Cell Imaging across additional organ systems and procedural environments,” CellTivity CEO Greg Bowles said. “CellTivity’s evolution and expanded focus is a major strategic move that holds significant promise for us and health professionals both in the U.S. and internationally who are showing a growing interest in our game-changing detection platform.”
The Van Gogh Microscopy System provides metabolic cellular imaging intended to help clinicians make timely intraprocedural decisions. CellTivity said it is investing in commercial infrastructure and product development as demand grows among clinicians seeking greater procedural precision, workflow integration and improved disease detection.
In gynecologic oncology, recently published research examined the technology’s use in evaluating lymph node tissue during cancer surgery. Investigators led by Dr. Matteo Pavone, a Rome-based gynecologist-obstetrician specializing in robotic, minimally invasive surgery and oncological gynecology, assessed real-time microscopic evaluation of lymph nodes in gynecologic malignancies and reported strong concordance with gold-standard histopathology.
“One of the greatest challenges during cancer surgery is obtaining real-time information whilst the operation is still underway,” Dr. Pavone said. “Dynamic Cell Imaging allows us to visualize cellular structure and activity in real time, providing a new level of understanding during the procedure, aiding decision-making, and at the same time preserving the sample for definitive histological examination and molecular analysis.”
Bowles said the work with Pavone demonstrates how the Van Gogh technology could support intraprocedural evaluation of lymph node tissue in gynecologic oncology.
“The findings reinforce the potential of our real-time cellular imaging platform to provide rapid microscopic insight during cancer surgery while preserving tissue for definitive pathology and downstream molecular analysis,” Bowles said.
CellTivity said the Van Gogh Microscopy System received CE registration in Europe late last year, allowing real-time diagnostic sampling support in medical facilities across the continent.
The company is also expanding clinical evaluation of the system into gastrointestinal indications, including pancreatic tissue assessment. The technology was demonstrated last month in pancreatic cancer and GI applications during the European Society of Gastrointestinal Endoscopy Conference in Milan.
CellTivity said it plans to continue collaborating with European oncology and endoscopy centers to evaluate how the Van Gogh system performs in additional procedural settings and cancer types.
“So far, the results have been extremely encouraging,” Bowles said. “They reinforce our strategic roadmap, eventually expanding the use for every biopsy procedure, improving the quality of care for patients globally.”
